Welcome to the e-CCO Library!

P431: Early mucosal healing at week 10 with ozanimod predicts clinical outcomes at week 52: Post hoc analysis of the phase 3 True North clinical trial
Year: 2022
Source: ECCO'22
Authors: Reinisch, W.(1);Axelrad, J.(2);Ahmad, H.A.(3);Pondel, M.(3);Ather, S.(3);Elegbe, A.(3);Sninsky, C.(4);Longman, R.(5);
Created: Friday, 11 February 2022, 3:52 PM
P431: Golimumab dried blood spot analysis (GOUDA): A prospective trial to validate golimumab concentration analysis using the dried blood spot methodology
Year: 2018
Source: ECCO '18 Vienna
Authors:

I. Detrez1*, E. Dreesen1, G. Van Assche2, S. Vermeire2, M. Ferrante2, A. Gils1

Created: Thursday, 21 February 2019, 9:14 AM
P431: Teduglutide use and nutritional outcomes in short bowel syndrome with intestinal failure: a real-world claims database analysis
Year: 2021
Source: ECCO'21 Virtual
Authors: Micic, D.(1);Jiang, J.(2);Chen, L.(2);Fan, T.(2);Mu, F.(3);Satija, A.(4);Downes, N.(5);Shrestha, S.(5);Wu, E.(3);Swallow, E.(6);Wojtowicz, A.(7);Raphael, B.P.(8);
Created: Wednesday, 2 June 2021, 4:12 PM
P431: Transabdominal ultrasonography to assess intestinal wall thickness and vascularity appears to predict therapeutic effects of steroid treatment in moderate-to-severe ulcerative colitis patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Ogashiwa*1, M. Murakami1, S. Tsuda1, M. Nishio1, Y. Kogure1, K. Kasahara1, K. Hirai2, Y. Fukuno2, M. Jin2, A. Hanzawa2, H. Yonezawa2, K. Numata3, H. Kimura1, R. Kunisaki1

Created: Friday, 22 February 2019, 9:49 AM
P431: Validation of a therapeutic drug monitoring test to measure the adalimumab biosimilar SB5 in comparison with the reference adalimumab
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. B. Ruiz-Argüello*1, A. Maguregui1, A. Martínez1, D. Nagore1

Created: Friday, 22 February 2019, 9:41 AM
P432 Effects and safety of a colon-long absorbing budesonide product in patients with mild to moderate ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Pigniczki, K. Szántó, M. Rutka, K. Farkas, A. Bálint, R. Bor, A. Fábián, Z. Szepes, T. Molnár

Created: Thursday, 30 January 2020, 10:12 AM
P432: Barriers to prescribing anti-TNF therapy in inflammatory bowel disease (IBD) across newly industrialised emerging market countries: an analysis of the ‘EXPLORE’ study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. D. Ye*1, J. K. Yamamoto Furusho2, M. Rana Qasim Khan3, O. Fadeeva3, D. Demuth4, J. Qian5, I. L. Khalif6, T. Chia-Hung7, M. Toruner8, A. H. Othman9, W. Chan10, E. Ponce de Leon11, M. Guennec12, C. Sison13, E. Uberti Foppa14, A. Armuzzi15

Created: Friday, 22 February 2019, 9:41 AM
P432: Does medical acceleration improve long-term outcomes in ulcerative colitis patients who are in clinical remission but have endoscopic mucosal inflammation?
Year: 2018
Source: ECCO '18 Vienna
Authors:

J.Y. Chang*, J.H. Cheon, Y. Park, S.J. Park, T.-I. Kim, W.-H. Kim

Created: Thursday, 21 February 2019, 9:14 AM
P432: MyChart application in addressing Inflammatory Bowel Disease patients’ concerns and impact on service utilisation
Year: 2021
Source: ECCO'21 Virtual
Authors: P Raman, K.(1);Agorogianni, A.(1);Hadjinicolaou, A.(1);Nightingale, A.(1);Mayhew, A.(1);Munro, R.(1);Raine, T.(1);McDermott, E.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P432: Patient perspectives on biosimilars: a European Federation of Crohn’s and Colitis Associations survey
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. Peyrin-Biroulet*1, S. Lönnfors2, S. Danese3, X. Roblin4, L. Avedano5, M. Greco5

Created: Friday, 22 February 2019, 9:49 AM
P432: Patient satisfaction and patient costs associated with telephone clinic appointments in Inflammatory Bowel Disease (IBD) following the pandemic
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Matini, L.(1)*;Stokes, E.A.(2);Parra Mujica, F.(3);Kormilitzin, A.(4);Kantschuster, R.(1);Punj Sharda, A.(1);Dunbar, G.(1);Song, K.(1);White, L.(1);Travis, S.P.L.(5);Walsh, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P432: Therapeutic approaches for perianal fistula in paediatric and adolescent onset Crohn's disease – a multicentre cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sebastian S.*1,2, Tzivinikos C.3, Drskova T.4, Hradsky O.4, Nair M.V.1,5, Sahnan K.6, Muhammed R.7, Devadason D.8, Parmar R.S.3, Crook K.6, Akbar A.6, Thomson M.5, Hart A.L.6

Created: Wednesday, 20 February 2019, 10:36 AM
P433 A real-world observational study assessing treatment persistence in ulcerative colitis patients receiving anti-TNF treatment (golimumab or adalimumab)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Hoque1, S. Boccaletti2, A. Puenpatom3, C. Brown2, C. Black3, J. Roberts4, I. Rajkovic4, G. Milligan4

Created: Thursday, 30 January 2020, 10:12 AM
P433: Aetiologies of iron deficiency-related anaemia in German patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Aksan*1,2, E. Leventi1,3, K. Farrag1,3, I. Mavrommataki1,3, A. Dignass4, J. Stein1,3

Created: Friday, 22 February 2019, 9:41 AM
P433: Canadian patient and caregiver perspectives on subsequent entry biologics / biosimilars for inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. Attara*1, R. Bailey2, B. Bressler3, J. Marshall4, R. Panaccione5, G. Aumais6

Created: Friday, 22 February 2019, 9:49 AM
P433: Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Panaccione, R.(1)*;D'Haens, G.(2);Seenan, J.P.(3);Caprioli, F.(4,5);Siegel, C.(6);Nakamura, M.(7);Wei, S.C.(8);Kligys, K.(9);Zhang, Y.(9);Zambrano, J.(9);Song, A.P.(9);Ferrante, M.(10);
Created: Friday, 14 July 2023, 11:05 AM
P433: Faecal calprotectin is correlated to endoscopic disease activity at Week 16 in IBD patients on vedolizumab therapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

R.W.M. Pauwels*, A.C. De Vries, C.J. Van der Woude

Created: Thursday, 21 February 2019, 9:14 AM
P433: Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc.
Year: 2022
Source: ECCO'22
Authors: Garcia-Alvarado, M.(1);Barrio, J.(2);Sierra-Ausin, M.(3);Arias, L.(4);Fernández-Salazar, L.(5);Fuentes Coronel, A.(6);Arias García, L.(7);García-Alonso, F.J.(8);García-Prada, M.(3);Legido, J.(4);Sánchez-Hernández, J.G.(9);Muñoz, F.(10);
Created: Friday, 11 February 2022, 3:52 PM
P433: Postsurgical recurrence in Crohn's disease. Multicenter study in the region of Murcia, Spain of GEMEII group
Year: 2017
Source: ECCO '17 Barcelona
Authors:

García Albert A.M.1, García-Paredes R.*2, Torrella Cortés E.3, Martinez-Jimenez T.4, Angel Rey J.M.4, García-Tercero I.2, Castillo Espinosa J.M.5, Torregrosa Lloret M.3, Chacόn Martínez S.3, Andreu Plaza J.6, Rodríguez Lozano A.2

Created: Wednesday, 20 February 2019, 10:36 AM